Abstract
The inhibition of protein degradation through the ubiquitin – proteasome pathway is a recently developed approach to cancer treatment which extends the range of cellular targets for chemotherapy. This therapeutic strategy is very interesting since the proteasomes carry out the regulated degradation of unnecessary or damaged cellular proteins, a process that is dysregulated in many cancer cells. Based on this hypothesis, the proteasome complex inhibitor bortezomib was approved for use in multiple myeloma patients by the US Food and Drug Administration (FDA) in 2003 and by the European Medicines Agency (EMEA) in 2004, and several new drugs with the same target and, sometimes, mechanism of action are currently under development. Interestingly, proteasome inhibitors have now also been tested in combination chemotherapy for the treatment of several solid tumors and it is likely that there will be more generalized use of these compounds in the near future. Despite its remarkable effectiveness, which led to it being rapidly approved for clinical use, some concern has been raised regarding the safety of bortezomib (and in general of proteasome inhibitors) since reduced degradation of damaged proteins has been postulated as being the basic mechanism of severe neurological diseases affecting the central nervous system. While this concern has not been confirmed by the clinical course of treated patients, from the first Phase I studies, it emerged that peripheral sensory neurotoxicity was one of the major dose-limiting toxicities. The main results from the use of proteasome inhibition in cancer chemotherapy and the implications for treatment on the nervous system will be reviewed.
Keywords: Protein degradation, ubiquitin-proteasome system, proteasome inhibition, protein aggregates, cancer, chemotherapy, neurotoxicity, neurodegenerative diseases
Current Medicinal Chemistry
Title: Proteasome Inhibition: A Promising Strategy for Treating Cancer, but What About Neurotoxicity?
Volume: 15 Issue: 29
Author(s): A. Gilardini, P. Marmiroli and G. Cavaletti
Affiliation:
Keywords: Protein degradation, ubiquitin-proteasome system, proteasome inhibition, protein aggregates, cancer, chemotherapy, neurotoxicity, neurodegenerative diseases
Abstract: The inhibition of protein degradation through the ubiquitin – proteasome pathway is a recently developed approach to cancer treatment which extends the range of cellular targets for chemotherapy. This therapeutic strategy is very interesting since the proteasomes carry out the regulated degradation of unnecessary or damaged cellular proteins, a process that is dysregulated in many cancer cells. Based on this hypothesis, the proteasome complex inhibitor bortezomib was approved for use in multiple myeloma patients by the US Food and Drug Administration (FDA) in 2003 and by the European Medicines Agency (EMEA) in 2004, and several new drugs with the same target and, sometimes, mechanism of action are currently under development. Interestingly, proteasome inhibitors have now also been tested in combination chemotherapy for the treatment of several solid tumors and it is likely that there will be more generalized use of these compounds in the near future. Despite its remarkable effectiveness, which led to it being rapidly approved for clinical use, some concern has been raised regarding the safety of bortezomib (and in general of proteasome inhibitors) since reduced degradation of damaged proteins has been postulated as being the basic mechanism of severe neurological diseases affecting the central nervous system. While this concern has not been confirmed by the clinical course of treated patients, from the first Phase I studies, it emerged that peripheral sensory neurotoxicity was one of the major dose-limiting toxicities. The main results from the use of proteasome inhibition in cancer chemotherapy and the implications for treatment on the nervous system will be reviewed.
Export Options
About this article
Cite this article as:
Gilardini A., Marmiroli P. and Cavaletti G., Proteasome Inhibition: A Promising Strategy for Treating Cancer, but What About Neurotoxicity?, Current Medicinal Chemistry 2008; 15 (29) . https://dx.doi.org/10.2174/092986708786848622
DOI https://dx.doi.org/10.2174/092986708786848622 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Angiogenesis Inhibitors: Current & Future Directions
Current Pharmaceutical Design Immunomodulation in Polytrauma and Polymicrobial Sepsis - Where Do We Stand?
Recent Patents on Inflammation & Allergy Drug Discovery Cancer Pharmacogenomics: Germline DNA, Tumor DNA, or Both?
Current Pharmacogenomics Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy
Current Drug Targets Application of Molecular Diagnostics to the Evaluation of the Surgical Approach to Thyroid Cancer
Current Genomics Advances in Whole Genome Sequencing Technology
Current Pharmaceutical Biotechnology Potentials of Polymeric Nanoparticle as Drug Carrier for Cancer Therapy: With a Special Reference to Pharmacokinetic Parameters
Current Drug Metabolism Inhibiting HSP90 to Treat Cancer: A Strategy in Evolution
Current Molecular Medicine Editorial [Hot Topic: Tumor Immunology (Guest Editors: Bharat H. Joshi and Raj K. Puri)]
Current Molecular Medicine Cucurbitacins as Inducers of Cell Death and a Rich Source of Potential Anticancer Compounds
Current Pharmaceutical Design HR-MAS NMR Spectroscopy: A Practical Guide for Natural Samples
Current Organic Chemistry Diagnostic and Therapeutic Applications of Recombinant Antibodies:Targeting the Extra-Domain B of Fibronectin, A Marker of Tumor Angiogenesis
Current Pharmaceutical Design Enzymes To Die For: Exploiting Nucleotide Metabolizing Enzymes for Cancer Gene Therapy
Current Gene Therapy Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors from the Natural Origin: A Recent Perspective
Anti-Cancer Agents in Medicinal Chemistry Carbonic Anhydrase Inhibitors Developed Through ‘Click Tailing’
Current Pharmaceutical Design Editorial (Hot Topic: Recent Development of Molecular Targeted Anti-Cancer Agents)
Anti-Cancer Agents in Medicinal Chemistry Nano-Delivery in Pediatric Tumors: Looking Back, Moving Forward
Anti-Cancer Agents in Medicinal Chemistry Minichromosome Maintenance Complex is Required for Checkpoint Kinase 2 Chromatin Loading and its Phosphorylation to DNA Damage Response in SCC-4 Cells
Protein & Peptide Letters Gastrointestinal Stromal Tumors: A Paradigm for Therapeutic Options in Solid Organ Tumors
Mini-Reviews in Medicinal Chemistry Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy
Current Cancer Drug Targets